FDA Clears Specialty Applications for Radiology Platform
By MedImaging International staff writers Posted on 03 Jul 2017 |
Image: The Longitudinal Brain Imaging (LoBI) is the newest Intellispace 9.0 portal clinical application approved US distribution (Photo courtesy of Philips Healthcare).
The US FDA has provided 510(k) clearance for new oncology, neurology and cardiology advanced applications for image comparison and analysis, and evaluation treatments and therapy response assessment.
The latest release of the clinical informatics platform now includes new advanced clinical applications for multi-modality tumor tracking, optimized lung-nodule assessment, and longitudinal brain imaging.
The new applications are for the Royal Philips (Amsterdam, the Netherlands) IntelliSpace Portal 9.0 portal, and are now available for marketing in the US. The most recent innovation cleared by the FDA was the Longitudinal Brain Imaging (LoBI) application that can be used to analyze brain images for tracking neurodegenerative disorders including stroke, Multiple Sclerosis (MS), and Alzheimer's disease. New oncology functionality includes qEASL, part of the Multi-Modality Tumor Tracking application, for enhanced tumor volume measurements using Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans. The new Lung Nodule Assessment tool provides information about lung nodules from a single CT study, and can also track them across multiple studies.
The IntelliSpace Portal 9.0 portal already offers more than 70 radiology, cardiology, oncology, and neurology applications, and provides a comprehensive overview of a patient’s health. The new applications can enable clinicians to evaluate patients faster, across modalities, and to track therapy response over time.
Leiden University Medical Center professor of neuroradiology, Mark van Buchem, said, "Analytics applications optimized for clinical decision support and longitudinal and quantified patient tracking are becoming increasingly important to radiologists. They can help visualize and quantify very subtle manifestations of disease and differences over time that may not be seen with the naked eye. IntelliSpace Portal 9.0 integrates into our existing workflow and adds greatly to our patient care."
The latest release of the clinical informatics platform now includes new advanced clinical applications for multi-modality tumor tracking, optimized lung-nodule assessment, and longitudinal brain imaging.
The new applications are for the Royal Philips (Amsterdam, the Netherlands) IntelliSpace Portal 9.0 portal, and are now available for marketing in the US. The most recent innovation cleared by the FDA was the Longitudinal Brain Imaging (LoBI) application that can be used to analyze brain images for tracking neurodegenerative disorders including stroke, Multiple Sclerosis (MS), and Alzheimer's disease. New oncology functionality includes qEASL, part of the Multi-Modality Tumor Tracking application, for enhanced tumor volume measurements using Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans. The new Lung Nodule Assessment tool provides information about lung nodules from a single CT study, and can also track them across multiple studies.
The IntelliSpace Portal 9.0 portal already offers more than 70 radiology, cardiology, oncology, and neurology applications, and provides a comprehensive overview of a patient’s health. The new applications can enable clinicians to evaluate patients faster, across modalities, and to track therapy response over time.
Leiden University Medical Center professor of neuroradiology, Mark van Buchem, said, "Analytics applications optimized for clinical decision support and longitudinal and quantified patient tracking are becoming increasingly important to radiologists. They can help visualize and quantify very subtle manifestations of disease and differences over time that may not be seen with the naked eye. IntelliSpace Portal 9.0 integrates into our existing workflow and adds greatly to our patient care."
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer